https:\/\/informaconnect.com<\/a>)<\/p>\nCountry-Level Investments & Funding for the Cell and gene therapy quality control and analytics Industry
\n
\nU.S.: The National Institutes of Health (NIH) collaborated with the Food and Drug Administration (FDA) to provide funding for regenerative medicine research. The government has allocated more than $40 billion annually for pharmaceutical and biotechnology research and development (R&D) activities.\u00a0
\nCanada: Ngen has invested $10.5 million in a $34.8 million project led by OmnioBio for the development of commercial-scale CGT manufacturing. These investments have enhanced automated systems, quality management, and cutting-edge analytics, supporting domestic capacity building.\u00a0
\nGermany: In June 2024, the German government applied national strategies for gene & cell-based therapies. These initiatives include funding programs from the Federal Ministry of Education and Research (BMBF).
\nUK: In 2023, 55% of European venture capital funding for CGT was secured by UK companies. The UK\u2019s biotech companies play a vital role in private investments for cell & gene therapies.\u00a0
\nChina: In 2023, Chinese biotech secured around $20.61 billion in funding from 69 companies, with an average of $299 million per firm. These investments demonstrate a transition from a focus on generics for innovation and attracting global pharmaceutical companies through licensing deals for novel drugs.\u00a0
<\/p>\n
Top Companies in the Cell and gene therapy quality control and analytics Market<\/p>\n
Tier I: Market Leaders<\/p>\n
These companies are dominant in the market, offering comprehensive quality control and analytical solutions across various stages of cell and gene therapy development.<\/p>\n
\n
\n
\nCompany
\nKey Offerings
\n
\n
\nThermo Fisher Scientific
\nBroad portfolio including next-generation sequencing, PCR\/qPCR, and AI-driven analytics platforms.
\n
\n
\nLonza Group
\nExtensive services in cell and gene therapy manufacturing, including quality control and analytics.
\n
\n
\nMerck KGaA
\nOffers a range of analytical solutions and consumables for cell and gene therapy applications.
\n
\n
\nBio-Rad Laboratories
\nProvides analytical instruments and reagents for gene therapy quality control.
\n
\n
\nQIAGEN
\n
<\/p>\n
Specializes in molecular testing and analytical solutions for gene therapy.<\/p>\n
<\/p>\n
\u00a0<\/p>\n
\n
\n
\n
<\/p>\n
Tier II: Established Players<\/p>\n
These companies have a significant presence in the market, offering specialized services and products that support cell and gene therapy quality control and analytics.<\/p>\n
\n
\n
\nCompany
\nKey Offerings
\n
\n
\nCharles River Laboratories
\nProvides comprehensive services including quality control testing for gene therapies
\n
\n
\nBio-Techne Corporation
\nOffers tools and reagents for cell and gene therapy research and development.
\n
\n
\nWuXi AppTec
\nProvides integrated services including quality control testing for gene therapies.
\n
\n
\nCatalent, Inc
\nSpecializes in gene therapy manufacturing and quality control services.
\n
\n
\nEurofins Scientific
\n
<\/p>\n
Offers analytical testing services for gene therapy products.<\/p>\n
\n
\n
\n
<\/p>\n
Tier III: Emerging and Niche Players<\/p>\n
These companies are emerging players or niche providers that contribute to specific aspects of cell and gene therapy quality control and analytics.<\/p>\n
\n
\n
\nCompany
\nKey Offerings
\n
\n
\nIQVIA
\nProvides data analytics and technology solutions for gene therapy development.
\n
\n
\nF. Hoffmann-La Roche Ltd.
\nOffers diagnostic solutions supporting gene therapy applications
\n
\n
\nSamsung Biologics
\nProvides contract development and manufacturing services with quality control capabilities.
\n
\n
\nSangamo Therapeutics
\nFocuses on gene therapy development with integrated quality control processes.
\n
\n
\nGalapagos NV
\n
<\/p>\n
Engages in cell therapy development with an emphasis on quality control.<\/p>\n
\n\u00a0
\n
\n
\n
<\/p>\n
Recent Developments\u00a0
\n
\nIn November 2024, NewBiologix launched the Xcell rAAV platform to streamline and accelerate rAAV production for gene and cell therapy. Powered by the engineered Xcell Eng-HEK293 cell line, the platform enables high-quality rAAV production via transient transfection. It offers an end-to-end solution, from DNA synthesis to clinical-grade purification, while built-in analytics ensure quality by assessing capsid ratios, gene integrity, and contaminants, reducing development time, cost, and risk.\u00a0(Source: https:\/\/www.regmednet.com<\/a>)
\nIn April 2024, Cellares unveiled Cell Q\u2122, the first automated quality control (QC) workcell for cell therapy manufacturing. Exclusive to its Smart Factories, Cell Q\u2122 streamlines the traditionally manual and costly QC process, offering significantly improved throughput, cost-efficiency, and consistency.\u00a0(Source: https:\/\/www.cellares.com<\/a>)
<\/p>\nSegment Covered in the Report<\/p>\n
By Testing Type\u00a0<\/p>\n
\nSterility Testing\u00a0
\nIdentity Testing\u00a0
\nPotency Testing\u00a0
\nMycoplasma Testing\u00a0
\nEndotoxin Testing\u00a0
\nOthers\u00a0
<\/p>\n
By Analytical Method\u00a0<\/p>\n
\nFlow Cytometry\u00a0
\nPolymerase Chain Reaction (PCR)\u00a0
\nHigh-Performance Liquid Chromatography (HPLC)\u00a0
\nMass Spectrometry\u00a0
\nEnzyme-Linked Immunosorbent Assay (ELISA)\u00a0
\nOthers\u00a0
<\/p>\n
By Application Area<\/p>\n
\nOncology
\nGenetic Disorders
\nCardiovascular Diseases
\nInfectious Diseases
\nOthers
<\/p>\n
By End-User<\/p>\n
\nPharmaceutical & Biotechnology Companies
\nContract Development and Manufacturing Organizations (CDMOs)
\nAcademic & Research Institutes
\nOthers
<\/p>\n
By Region<\/p>\n
\nNorth America
\nEurope
\nAsia-Pacific
\nLatin America
\nMiddle East & Africa
<\/p>\n","protected":false},"excerpt":{"rendered":"What is the Cell and Gene Therapy Quality Control and Analytics Market Size? The global cell and gene…\n","protected":false},"author":2,"featured_media":77813,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12],"tags":[72,51062,61,60,123],"class_list":["post-77812","post","type-post","status-publish","format-standard","has-post-thumbnail","category-markets","tag-business","tag-cell-and-gene-therapy-quality-control-and-analytics-market","tag-ie","tag-ireland","tag-markets"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/77812","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=77812"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/77812\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/77813"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=77812"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=77812"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=77812"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"Cell](\"https:\/\/www.newsbeep.com\/ie\/wp-content\/uploads\/2025\/10\/cell-and-gene-therapy-quality-control-and-analytics-market-size.webp.webp\" "\\"Cell")